Immunovant Ends Cutaneous Lupus Study After IMVT-1402 Fails to Beat Placebo
Immunovant ends IMVT-1402 in cutaneous lupus after a 57-patient study missed its CLASI-A primary endpoint. Other programs remain on track.
/ 3 items
#IMVT↓
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Wolfe Research Upgrades Immunovant to Outperform with $50 Target
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.